EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC)

Cerise Tang, Deepak Poduval, Suzanna Lee, Justine Panian, Ava Saidian, Rishabh Rout, David van Dijk, Rana R McKay, David A Braun iD

BMJ Oncology · 2026-07 · 5 (2) · e001031

DOI: 10.1136/bmjonc-2025-001031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMJ Oncology, online erschienen am 02.07.2026. Verfasst von Cerise Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Defense Early Career Investigator grant, NIH/NCI, Kidney Cancer Association (KCA) Trailblazer Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective Immune checkpoint inhibitors (ICIs) have demonstrated durable clinical benefit in a subset of patients with metastatic renal cell carcinoma (RCC), yet the molecular features that govern therapeutic response within the primary tumour remain poorly defined. This is of particular importance in the current era, where cytoreductive nephrectomy is less commonly performed and many patients with metastatic disease still have the primary RCC tumour in place. To deepen our understanding of ICI response in the primary tumour and to understand the evolution of RCC on ICI, we conducted a comprehensive genomic analysis of paired pretreatment and post-treatment primary RCC tumours treated with ICI. Design, setting and participants We performed a multimodal analysis of 46 ICI-treated primary RCC tumour specimens from 33 patients, including 13 matched pretreatment biopsies and post-treatment nephrectomies to investigate the genomic and transcriptomic evolution of tumours exposed to ICI therapy. Seventeen samples were from responders (>30% radiographic shrinkage, n=4 pretreatment, n=13 post-treatment) and 29 samples were from non-responders (

Schlagwörter

Stichwörter der Autor:innen

ImmunotherapyKidney cancer

Autor:innen und Institutionen

  • Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Division of Hematology-Oncology, University of California San Diego Department of Medicine, La Jolla, California, USA.
  • Department of Urology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Yale Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: David A Braun

Förderung

  • Department of Defense Early Career Investigator grant
  • NIH/NCI
  • Kidney Cancer Association (KCA) Trailblazer Award
  • Louis Goodman and Alfred Gilman Yale Scholar Fund
  • Yale Cancer Center

Zitieren

APA

Tang, C., Poduval, D., Lee, S., Panian, J., Saidian, A., Rout, R., van Dijk, D., McKay, R. R., & Braun, D. A. (2026). Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC). BMJ Oncology, 5(2), e001031. https://doi.org/10.1136/bmjonc-2025-001031

Vancouver

Tang C, Poduval D, Lee S, Panian J, Saidian A, Rout R, et al. Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC). BMJ Oncology. 2026;5(2):e001031. doi:10.1136/bmjonc-2025-001031

BibTeX
@article{Tang2026,
  author = {Tang, Cerise and Poduval, Deepak and Lee, Suzanna and Panian, Justine and Saidian, Ava and Rout, Rishabh and van Dijk, David and McKay, Rana R and Braun, David A},
  title = {Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC)},
  journal = {BMJ Oncology},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {e001031},
  doi = {10.1136/bmjonc-2025-001031}
}
Kostenlos starten →